Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mepolizumab by GSK for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to...
Belimumab by GSK for Cryoglobulinemia: Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase II for Cryoglobulinemia. According to GlobalData, Phase II drugs...
Dostarlimab by GSK for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....
Influenza [strain A/H5N8] vaccine by GSK for Influenzavirus A Infections: Likelihood of Approval
Influenza [strain A/H5N8] vaccine is under clinical development by GSK and currently in Phase II for Influenzavirus A Infections. According...
Camlipixant by GSK for Chronic Cough: Likelihood of Approval
Camlipixant is under clinical development by GSK and currently in Phase III for Chronic Cough. According to GlobalData, Phase III...
Niraparib by GSK for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Niraparib by GSK for Uterine Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II...
Feladilimab by GSK for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
Belantamab mafodotin by GSK for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Belantamab mafodotin by GSK for Amyloidosis: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Amyloidosis. According to GlobalData, Phase II...
Belantamab mafodotin by GSK for Relapsed Multiple Myeloma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Pre-Registration for Relapsed Multiple Myeloma. According to GlobalData, Pre-Registration...
Belantamab mafodotin by GSK for Refractory Multiple Myeloma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Pre-Registration for Refractory Multiple Myeloma. According to GlobalData, Pre-Registration...
Feladilimab by GSK for Non-Small Cell Lung Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Dostarlimab by GSK for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Feladilimab by GSK for Non-Small Cell Lung Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
GSK-3888550A by GSK for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
GSK-3888550A is under clinical development by GSK and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According to...
GSK-4382276A by GSK for Seasonal Influenza: Likelihood of Approval
GSK-4382276A is under clinical development by GSK and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of GSK's Linerixibat?
Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of GSK's Cobolimab?
Cobolimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Non-Small Cell Lung Carcinoma;Squamous Non-Small...
Risk adjusted net present value: What is the current valuation of GSK's GSK-4178116A?
GSK-4178116A is a live attenuated vaccine commercialized by GSK, with a leading Phase II program in Chicken Pox. According to...